Huazhong University of Science and Technology Tongji Hospital Demonstrates In Vivo CAR-T Therapy, Achieving Cost Reduction and Immune Reset for Multiple Sclerosis

Chosunbiz South Korea

Overview

A research team at Huazhong University of Science and Technology Tongji Hospital has demonstrated in vivo CAR-T therapy for autoimmune diseases like multiple sclerosis, successfully reducing manufacturing and logistics costs compared to traditional ex vivo production. This innovative in vivo approach directly delivers CAR-T genetic information to the patient’s T-cells using a lentiviral vector, enabling therapeutic cell generation within the body. This holds the potential to overcome the high costs and complex manufacturing processes currently associated with CAR-T therapies.

In Depth

Key Findings

A research team at Huazhong University of Science and Technology Tongji Hospital has demonstrated a groundbreaking “in vivo CAR-T” therapy for autoimmune diseases, including multiple sclerosis (MS). This novel approach shows potential for significantly reducing treatment costs by eliminating the complex processes and logistics required for traditional ex vivo CAR-T manufacturing. The technology is expected to contribute to a fundamental cure for autoimmune diseases by directly generating CAR-T cells within the patient’s body and effectively resetting the immune system.

Technical / Clinical Details

This in vivo CAR-T therapy functions by directly administering a lentiviral vector to the patient. The lentivirus efficiently delivers the chimeric antigen receptor (CAR) genetic information to the patient’s own T-cells, prompting the T-cells to transform into CAR-T cells within the patient’s body. This in vivo gene delivery approach differs from traditional ex vivo approaches in several key aspects:

• Simplified Manufacturing Process: It eliminates the complex steps of collecting T-cells from the patient, genetically modifying them ex vivo, culturing, and expanding them.
• Streamlined Logistics: It bypasses the time-consuming and costly transportation processes involved in delivering modified CAR-T cells from an external facility back to the patient.
• Cost Reduction: It can significantly reduce expenses associated with manufacturing facilities, specialized personnel, and stringent quality control requirements.

This approach is expected to efficiently generate CAR-T cells targeting self-reactive T-cells in vivo, thereby suppressing autoimmune responses in multiple sclerosis and restoring immune system balance.

Background & Context

While CAR-T cell therapy has achieved remarkable success in certain blood cancers, its manufacturing faces significant challenges: it requires highly specialized facilities, stringent quality control, high costs, and customized “manufacturing batches” for each patient. For applications in autoimmune diseases, treatment cost-effectiveness and accessibility are major barriers. In vivo CAR-T therapy directly addresses these challenges and holds the potential to increase the accessibility of CAR-T therapy for a broader range of diseases in the future. This technology is viewed as a promising solution to the “scale-out problem” of CAR-T treatment (the burden of personalized production).

Strategic Significance & Outlook

The proof-of-concept for in vivo CAR-T therapy by Huazhong University of Science and Technology Tongji Hospital represents a breakthrough with the potential to revolutionize autoimmune disease treatment. The simplification of manufacturing costs and logistics will make this expensive therapy a more viable option for a wider patient population. If this technology progresses further in clinical development and demonstrates safety and efficacy on a larger scale, its application is expected to extend beyond multiple sclerosis to other autoimmune diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis). Ultimately, in vivo CAR-T therapy holds the potential to accelerate the commercialization of cell therapies and establish a new therapeutic paradigm that dramatically improves patients’ quality of life.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

• Your email and selected fields are used only to deliver the newsletter.
• We never share your information with third parties.
• You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Agree & Continue ▶

Takes about a minute · Unsubscribe anytime